Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

被引:75
作者
Schnittger, Susanne [1 ]
Bacher, Ulrike [1 ]
Haferlach, Claudia [1 ]
Alpermann, Tamara [1 ]
Kern, Wolfgang [1 ]
Haferlach, Torsten [1 ]
机构
[1] MLL Munich Leukemia Lab, D-81377 Munich, Germany
关键词
ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; FOLLOW-UP; IMPACT; SIZE; IDENTIFICATION; CYTOGENETICS; DIAGNOSIS;
D O I
10.1002/gcc.21975
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In acute myeloid leukemia (AML) mutations in the juxtamembrane and tyrosine kinase 1 domain (exons 1315) of the FLT3 gene (FLT3-ITD/LM) are heterogeneous with respect to mutation load, size, and localization. We characterized length and structure of these mutations by fragment analysis and sequencing in 689 AML which were identified among 3,365 (20.5%) newly diagnosed AML (1,803 males, 1,562 females; 15.891.8 years). Mutations were heterogeneous in length (median: 63, range: 31,236 nucleotides; nt). Most frequent were sizes of 21 (8.4%) or 24 nt (6.0%). Ninety-one different insertion sites were observed (between nt 1,788 and 1,934, according to accession FLT3 [Ensembl/Havana merge: ENSG00000122025] with nt 1,856 (n = 41) and 1,863 (n = 35) being most frequent. In addition, 89 different insertion end points were observed between nt 1,790 and 1,994. FLT3-mutation/wild-type ratio was available in 615 patients (median, 0.80; range 0.03181.73). 128 Patients (20.8%) had ratios <0.3, 334 (54.3%) had ratio =0.3 <1, 118 (19.2%) =1, and 35 (5.7%) showed complete loss of the FLT3-wild-type allele. Overall (OS) and event-free (EFS) survival were better for FLT3-negative than FLT3mut normal karyotype patients (P = 0.078 and P = 0.004, respectively) and patients with low level FLT3-mutations had significantly longer OS and EFS compared with high level mutations (FLT3-mutation/wild-type ratio =1) (P < 0.001 and P = 0.002, respectively). The length of the mutation had no prognostic impact. Mutations localized more 5' were associated with better outcome than more 3'mutations, but no strict association to certain functional domains was detected. In conclusion, FLT3-mutations are extremely heterogenous with mutation load being the most relevant parameter. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:910 / 924
页数:15
相关论文
共 20 条
  • [1] PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) : 620 - 625
  • [2] Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor
    Breitenbuecher, Frank
    Schnittger, Susanne
    Grundler, Rebekka
    Markova, Boyka
    Carius, Birgit
    Brecht, Alexandra
    Duyster, Justus
    Haferlach, Torsten
    Huber, Christoph
    Fischer, Thomas
    [J]. BLOOD, 2009, 113 (17) : 4074 - 4077
  • [3] Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
    Buechner, Thomas
    Berdel, Wolfgang E.
    Haferlach, Claudia
    Haferlach, Torsten
    Schnittger, Susanne
    Mueller-Tidow, Carsten
    Braess, Jan
    Spiekermann, Karsten
    Kienast, Joachim
    Staib, Peter
    Grueneisen, Andreas
    Kern, Wolfgang
    Reichle, Albrecht
    Maschmeyer, Georg
    Aul, Carlo
    Lengfelder, Eva
    Sauerland, Maria-Cristina
    Heinecke, Achim
    Woermann, Bernhard
    Hiddemann, Wolfgang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) : 61 - 69
  • [4] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    Cheson, BD
    Bennett, JM
    Kopecky, KJ
    Büchner, T
    Willman, CL
    Estey, EH
    Schiffer, CA
    Döhner, H
    Tallman, MS
    Lister, TA
    LoCocco, F
    Willemze, R
    Biondi, A
    Hiddemann, W
    Larson, RA
    Löwenberg, B
    Sanz, MA
    Head, DR
    Ohno, R
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4642 - 4649
  • [5] The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
    Gale, Rosemary E.
    Green, Claire
    Allen, Christopher
    Mead, Adam J.
    Burnett, Alan K.
    Hils, Robert K.
    Linch, David C.
    [J]. BLOOD, 2008, 111 (05) : 2776 - 2784
  • [6] Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2
    Heiss, Elke
    Masson, Kristina
    Sundberg, Christina
    Pedersen, Malin
    Sun, Jianmin
    Bengtsson, Susanne
    Ronnstrand, Lars
    [J]. BLOOD, 2006, 108 (05) : 1542 - 1550
  • [7] Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
    Kayser, Sabine
    Schlenk, Richard F.
    Londono, Martina Correa
    Breitenbuecher, Frank
    Wittke, Kerstin
    Du, Juan
    Groner, Silja
    Spaeth, Daniela
    Krauter, Juergen
    Ganser, Arnold
    Doehner, Hartmut
    Fischer, Thomas
    Doehner, Konstanze
    [J]. BLOOD, 2009, 114 (12) : 2386 - 2392
  • [8] Loffler H., 2004, Atlas of Clinical Hematology, V6th
  • [9] Structural and numerical variation of FLT3/ITD in pediatric AML
    Meshinchi, Soheil
    Stirewalt, Derek L.
    Alonzo, Todd A.
    Boggon, Titus J.
    Gerbing, Robert B.
    Rocnik, Jennifer L.
    Lange, Beverly J.
    Gilliland, D. Gary
    Radich, Jerald P.
    [J]. BLOOD, 2008, 111 (10) : 4930 - 4933
  • [10] The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients
    Ponziani, V.
    Gianfaldoni, G.
    Mannelli, F.
    Leoni, F.
    Ciolli, S.
    Guglielmelli, P.
    Antonioli, E.
    Longo, G.
    Bosi, A.
    Vannucchi, A. M.
    [J]. LEUKEMIA, 2006, 20 (11) : 2074 - 2076